We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US and UK-based clinical stage biotech Immune Regulation has signed a deal with DynPort Vaccine Company to jointly evaluate the potential of the former's ILR201104 to treat COVID-19 related Acute Respiratory Distress Syndrome (ARDS) in US clinical trials.